| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_259045c6eba6e2c5d338b84e0a88b571 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-20 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-163
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3046
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57419
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57492 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18 |
| filingDate |
2003-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d4aaa7745fe626375663013c9acaa62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5535d4ada27c12801d50e1fdafd5eefe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e5db1651e3e8f3c3cab178e5665411de
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_502f00cf74d057eeb8af1796c43c87f5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4efc0ea1dc28e2f487f2e6cff62ec22a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_813a2eb793b7337effa617ecd02e165a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0c0b5a575ef2f40ff3617a4331e050b0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1ec755ea418300a9052c40238f5e0a80
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f604d7b4a5ed9200aff28178f7f36580
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a3ae8a9bb293f242ab322fcf04aff6cd |
| publicationDate |
2005-01-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20050003795-A |
| titleOfInvention |
Monoclonal antibody specific for human Calcyclin and Siah-1-interacting Protein and fusion cell strain producing the same |
| abstract |
The present invention relates to a monoclonal antibody against human CacyBP / SIP and a fusion cell line producing the same, and more particularly to CacyBP / SIP (Calcyclin and Siah-1-interacting Protein) having increased expression in human colorectal cancer tissues. As a specifically recognized antibody, the present invention relates to a monoclonal antibody produced by using a recombinant protein comprising an amino-terminal sequence of CacyBP / SIP as an antigen and a fusion cell line producing the same. Since the antibody of the present invention and the fusion cell line producing the same have little known role on the mechanism of oncogenesis by binding to S100A6 overexpressed in specific tumor cells, it is further studied and the specificity of the intracellular function of CacyBP / SIP protein. Antigen-antibody binding may be useful for clinical diagnosis of cancer. |
| priorityDate |
2003-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |